Oral bisphosphonates and colon cancer: an update
- PMID: 26288666
- PMCID: PMC4530382
- DOI: 10.1177/1759720X15582144
Oral bisphosphonates and colon cancer: an update
Abstract
Bisphosphonates (BPs) are widely used as the main treatment for osteoporosis. In vitro and animal studies suggest that use of BPs may have a potential for colorectal cancer (CRC) prevention. Safety and efficacy in terms of osteoporosis prevention have only been evaluated in randomized controlled trials (RCTs) of relatively short duration (3-5 years), with smaller extension studies. The evidence for a benefit beyond 5 years is limited and intake of BPs has not shown any relationship with CRC in intervention studies. Observational studies and meta-analysis have shown unchanged or decreased risk of CRC. BPs used for treatment and prevention of osteoporosis should not be applied for prevention of CRC in clinical practice.
Keywords: bisphosphonates; colorectal cancer; risk.
Conflict of interest statement
References
-
- Black D., Schwartz A., Ensrud K., Cauley J., Levis S., Quandt S., et al. (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial, JAMA, 296: 2927–2938. - PubMed
-
- Böhning D. (2000) Computer-assisted Analysis of Mixtures and Applications: Meta-analysis, Disease Mapping and Others. Boca Raton, FL: Chapman & Hall/CRC Press.
-
- Bone H., Hosking D., Devogelaer J., Tucci J., Emkey R., Tonino R., et al. (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women, New Engl J Med 350: 1189–1199. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
